US Pharm. 2011;36(1):60.
Watson Pharmaceuticals, Inc., and Natco Pharma Limited entered into an exclusive U.S. development and license agreement to develop and commercialize lenalidomide 5-, 10-, 15-, and 25-mg tablets. The companies also confirmed that Natco has filed an ANDA with the FDA for approval to market its lenalidomide 5-, 10-, 15-, and 25-mg product. Natco's lenalidomide tablets are generic versions of Revlimid Tablets (Celgene).
